May 09, 2018 - Genomic Health, Inc. (NASDAQ:GHDX) has filed a financial statement reporting Earnings Per Share Basic And Diluted of $-0 USD. Previously, on November 09, 2017, Genomic Health, Inc. reported Earnings Per Share Basic And Diluted of $-0 USD.

Period EndPeriodValue
2018-03-31 2018-Q1 -0.11
2017-09-30 2017-Q3 -0.06
2017-06-30 2017-Q2 -0.08
2017-03-31 2017-Q1 -0.02
2016-09-30 2016-Q3 -0.08
2016-06-30 2016-Q2 -0.18
2016-03-31 2016-Q1 -0.19
2015-12-31 2015-Q4 -0.08
2015-09-30 2015-Q3 -0.36
2015-06-30 2015-Q2 -0.29
2015-03-31 2015-Q1 -0.3
2014-12-31 2014-Q4 -0.2
2014-09-30 2014-Q3 -0.2
2014-06-30 2014-Q2 -0.15
2014-03-31 2014-Q1 -0.24
2013-06-30 2013-Q2 -0.1
2013-03-31 2013-Q1 -0.03

Other Interesting Charts

Accrued Collaboration Expense Current - Accrued Expenses Current - Allocated Share Based Compensation Expense - Contracts Revenue - Costs And Expenses - Current Federal Tax Expense Benefit - Current Foreign Tax Expense Benefit - Current State And Local Tax Expense Benefit - Deferred Federal Income Tax Expense Benefit - Deferred Income Tax Expense Benefit - Deferred State And Local Income Tax Expense Benefit - Deferred Tax Assets Tax Deferred Expense Compensation And Benefits - Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost - General And Administrative Expense - Income Tax Expense Benefit - Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate - Income Tax Reconciliation Nondeductible Expense Meals And Entertainment - Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost - Increase Decrease In Deferred Revenue - Increase Decrease In Prepaid Deferred Expense And Other Assets - Operating Leases Rent Expense Net - Other Nonoperating Income Expense - Prepaid Expense And Other Assets Current - Research And Development Expense - Revenues - Sales Revenue Goods Net - Selling And Marketing Expense - Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit - Unrecognized Tax Benefits Income Tax Penalties And Interest Expense -

Related News Stories

Here's Why You Should Invest in GNC Holdings (GNC) Right Now

2018-10-16 zacks
GNC Holdings, Inc. (GNC - Free Report) has been gaining investor confidence on stellar results over an extended period. Year to date, the company’s stock has outperformed its industry. The stock has gained 11.2% against the industry’s 2.2% rise. (0-2)

Amedisys to Buy Compassionate Care Hospice, Share Price Down

2018-10-15 zacks
Amedisys, Inc. (AMED - Free Report) recently inked an agreement to buy national hospice care provider —Compassionate Care Hospice. Amedisys is slated to pay $340 million, which includes $50 million in payments related to a tax asset and working capital for acquiring 100% ownership interest in Compassionate Care Hospice. The transaction is expected to close by Feb 1, 2019. (1-0)

Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus

2018-10-11 zacks
Myriad Genetics recently signed a commercialization plan with Pfizer Inc. (PFE - Free Report) for FDA approval to use its BRACAnalysis CDx as a companion diagnostic with the latter’s talazoparib. Meanwhile, Thermo Fisher Scientific Inc. (TMO - Free Report) announced the sixth licensing agreement for its B·R·A·H·M·S PCT (procalcitonin) biomarker. In fact, there are many similar developments that clearly point toward the rapid emergence of molecular diagnostics in the MedTech space. (4-0)

Here's Why You Should Invest in Genomic Health (GHDX) Now

2018-10-09 zacks
Genomic Health, Inc. (GHDX - Free Report) has been gaining investor confidence on stellar results over an extended period. Over the past year, the company’s share price has outperformed its industry. The stock has gained 103.2% against the industry’s 18.6% fall. Also, the company has fared better than the S&P 500’s 13.9% rise. (1-0)

Genomic Health's New Data on Oncotype DX GPS to Boost Uptake

2018-10-04 zacks
Genomic Health, Inc. (GHDX - Free Report) recently announced the publication of real-world clinical data supporting the use of the Oncotype DX Genomic Prostate Score (GPS) test, which has resulted in substantially greater use of active surveillance compared to no testing. Results of this new study were published in Reviews in Urology. (3-1)

CUSIP: 37244C101